Gynecomastia
physiopathology, evaluation and treatment
Keywords:
Breast, Gynecomastia, Surgery, Adolescent, Endocrine system diseasesAbstract
Gynecomastia (GM) is characterized by enlargement of the male breast, caused by glandular proliferation and fat deposition. GM is common and occurs in adolescents, adults and in old age. The aim of this review is to discuss the pathophysiology, etiology, evaluation and therapy of GM. A hormonal imbalance between estrogens and androgens is the key hallmark of GM generation. The etiology of GM is attributable to physiological factors, endocrine tumors or dysfunctions, non-endocrine diseases, drug use or idiopathic causes. Clinical evaluation must address diagnostic confirmation, search for an etiological factor and classify GM into severity grades to guide the treatment. A proposal for tailored therapy is presented. Weight loss, reassurance, pharmacotherapy with tamoxifen and surgical correction are the therapeutic options. For long-standing GM, the best results are generally achieved through surgery, combining liposuction and mammary adenectomy.
Downloads
References
Georgiadis E, Papandreou L, Evangelopoulou C, et al. Incidence of gynaecomastia in 954 young males and its relationship to somatometric parameters. Ann Hum Biol. 1994;21(6):579-87.
Nuttall FQ. Gynecomastia as a physical finding in normal men. J Clin Endocrinol Metab. 1979;48(2):338-40.
Nydick M, Bustos J, Dale JH Jr, Rawson RW. Gynecomastia in adolescent boys. JAMA. 1961;178:449-54.
Niewoehner CB, Nuttall FQ. Gynecomastia in a hospitalized male population. Am J Med. 1984;77(4):633-8.
Bannayan GA, Hajdu SI. Gynecomastia: clinicopathologic study of 351 cases. Am J Clin Pathol. 1972;57(4):431-7.
Moore NP. The oestrogenic potential of the phthalate esters. Reprod Toxicol. 2000;14(3):183-92.
Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, et al. Endocrine- disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev. 2009;30(4):293-342.
Sasano H, Kimura M, Shizawa S, Kimura N, Nagura H. Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study. J Clin Endocrinol Metabol. 1996;81(8):3063-7.
Calzada L, Torrs-Calleja J, Martinez JM, Pedrón N. Measurement of androgen and estrogen receptors in breast tissue from subjects with anabolic steroid-dependent gynecomastia. Life Sci. 2001;69(13):1465-9.
Rosen H, Webb ML, DiVasta AD, et al. Adolescent gynecomastia: not only an obesity issue. Ann Plast Surg. 2010;64(5):688-90.
Dimitrakakis C, Zhou J, Wang J, et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause. 2003;10(4):292-8.
Pearlman G, Carlson HE. Gynecomastia: an update. The Endocrinologist. 2006;16(2):109-15. Available from: http://www.mendeley.com/ research/gynecomastia-update/. Accessed in 2011 (Oct 19).
Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med. 2007;357(12):1229-37.
Narula HS, Carlson HE. Gynecomastia. Endocrinol Metab Clin North Am. 2007;36(2):497-519.
Thompson DF, Carter JR. Drug-induced gynecomastia. Pharmacotherapy. 1993;13(1):37-45.
Ismail AA, Barth JH. Endocrinology of gynaecomastia. Ann Clin Biochem. 2001;38(Pt 6):596-607.
Johnson RE, Murad MH. Gynecomastia: pathophysiology, evaluation, and management. Mayo Clin Proc. 2009;84(11):1010-5.
Braunstein GD. Environmental gynecomastia. Endocr Pract. 2008;14(4):409-11.
Durmaz E, Ozmert EN, Erkekoglu P, et al. Plasma phthalate levels in pubertal gynecomastia. Pediatrics. 2010;125(1):e122-9.
Stroheker T, Cabaton N, Nourdin G, et al. Evaluation of anti-androgenic activity of di-(2-ethylhexyl)phthalate. Toxicology. 2005;208(1):115-21.
Agency for Toxic Substances and Disease Registry. Toxicological profile for di-(2-ethylhexyl)-phthalate. Atlanta: Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry; 2002. Available from: http://www. atsdr.cdc.gov/toxprofiles/tp9-p.pdf. Accessed in 2011 (Oct 19).
Sattin RW, Roisin A, Kafrissen ME, Dungan JB, Farer LS. Epidemic of gynecomastia among illegal Haitian entrants. Public Health Rep. 1984;99(5):504-10.
Brody SA, Loriaux DL. Epidemic of gynecomastia among haitian refugees: exposure to an environmental antiandrogen. Endocr Pract. 2003;9(5):370-5.
Carlson HE, Kane P, Lei ZM, Li X, Rao CV. Presence of luteinizing hormone/human chorionic gonadotropin receptors in male breast tissues. J Clin Endocrinol Metab. 2004;89(8):4119-23.
Bird J, Li X, Lei ZM, et al. Luteinizing hormone and human chorionic gonadotropin decrease type 25 alpha-reductase and androgen receptor protein levels in women’s skin. J Clin Endocrinol Metab. 1998;83(5):1776-82.
Ruan W, Monaco ME, Kleinberg DL. Progesterone stimulates mammary gland ductal morphogenesis by synergizing with and enhancing insulin-like growth factor-I action. Endocrinology. 2005;146(3):1170-8.
Farthing MJ, Green JR, Edwards CR, Dawson AM. Progesterone, prolactin, and gynaecomastia in men with liver disease. Gut. 1982;23(4):276-9.
Nomura K, Suzuki H, Saji M, et al. High serum progesterone in hyperthyroid men with Graves’ disease. J Clin Endocrinol Metab. 1988;66(1):230-2.
Gill S, Peston D, Vonderhaar BK, Shousha S. Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. J Clin Pathol. 2001;54(12):956-60.
Correll CU. Effect of hyperprolactinemia during development in children and adolescents. J Clin Psychiatry. 2008;69(8):e24.
Ormandy CJ, Hall RE, Manning DL, et al. Coexpression and cross- regulation of the prolactin and sex steroid hormone receptors in breast cancer. J Clin Endocrinol Metab. 1997;82(11):3692-9.
Ruan W, Kleinberg DL. Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology. 1999;140(11):5075-81.
Braunstein GD. Gynecomastia. N Engl J Med. 1993;328(7):490-5.
Mazur T, Clopper RR. Pubertal disorders. Psychology and clinical management. Endocrinol Metab Clin North Am. 1991;20(1):211-30.
Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724-31.
Couillard C, Gagnon J, Bergeron J, et al. Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: the HERITAGE Family Study. J Clin Endocrinol Metab. 2000;85(3):1026-31.
Ford HC, Cooke RR, Keightley EA, Feek CM. Serum levels of free and bound testosterone in hyperthyroidism. Clin Endocrinol (Oxf ). 1992;36(2):187-92.
Lanfranco F, Kamischke A, Zitzmann M, Nieschlag E. Klinefelter’s syndrome. Lancet. 2004;364(9430):273-83.
Magro G, Gangemi P, Villari L, Greco P. Deciduoid-like stromal cells in a diabetic patient with bilateral gynecomastia: a potential diagnostic pitfall. Virchows Arch 2004;445(6):659-60.
García-Benayas T, Blanco F, Martín-Carbonero L, et al. Gynecomastia in HIV-infected patients receiving antiretroviral therapy. AIDS Res Hum Retroviruses. 2003;19(9):739-41.
Eckman A, Dobs A. Drug-induced gynecomastia. Expert Opin Drug Saf. 2008;7(6):691-702.
Goldman RD. Drug-induced gynecomastia in children and adolescents. Can Fam Physician. 2010;56(4):344-5.
Holzbeierlein JM. Managing complications of androgen deprivation therapy for prostate cancer. Urol Clin North Am. 2006;33(2):181-90, vi.
Sauer MA, Rifka SM, Hawks RL, Cutler GB Jr, Loriaux DL. Marijuana: interaction with the estrogen receptor. J Pharmacol Exp Ther. 1983;224(2):404-7.
Basaria S. Androgen abuse in athletes: detection and consequences. J Clin Endocrinol Metab. 2010;95(4):1533-43.
Hines SL, Tan WW, Yasrebi M, DePeri ER, Perez EA. The role of mammography in male patients with breast symptoms. Mayo Clin Proc. 2007;82(3):297-300.
Dialani V, Baum J, Mehta TS. Sonographic features of gynecomastia. J Ultrasound Med. 2010;29(4):539-47.
Olsson H, Bladstrom A, Alm P. Male gynecomastia and risk for malignant tumours--a cohort study. BMC Cancer. 2002;2:26.
Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet. 2006;367(9510):595-604.
Korde LA, Zujewski JA, Kamin L, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010;28(12):2114-22.
Sasco AJ, Lowenfels AB, Pasker-de Jong P. Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiologic factors. Int J Cancer. 1993;53(4):538-49.
Hultborn R, Hanson C, Köpf I, et al. Prevalence of Klinefelter’s syndrome in male breast cancer patients. Anticancer Res. 1997;17(6D):4293-7.
Rohrich RJ, Ha RY, Kenkel JM, Adams WP Jr. Classification and management of gynecomastia: defining the role of ultrasound- assisted liposuction. Plast Reconstr Surg. 2003;111(2):909-23; discussion 924-5.
Ratnam BV. A new classification and treatment protocol for gynecomastia. Aesthet Surg J. 2009;29(1):26-31.
Simon BE, Hoffman S, Kahn S. Classification and surgical correction of gynecomastia. Plast Reconstr Surg. 1973;51(1):48-52.
Cordova A, Moschella F. Algorithm for clinical evaluation and surgical treatment of gynaecomastia. J Plast Reconstr Aesthet Surg. 2008;61(1):41-9.
Hammond DC. Surgical correction of gynecomastia. Plast Reconstr Surg. 2009;124(1 Suppl):61e-68e.
Jones DJ, Holt SD, Surtees P, Davison DJ, Coptcoat MJ. A comparison of danazol and placebo in the treatment of adult idiopathic gynaecomastia: results of a prospective study in 55 patients. Ann R Coll Surg Engl. 1990;72(5):296-8.
Buckle R. Danazol therapy in gynaecomastia; recent experience and indications for therapy. Postgrad Med J. 1979;55 Suppl 5:71-8.
Eberle AJ, Sparrow JT, Keenan BS. Treatment of persistent pubertal gynecomastia with dihydrotestosterone heptanoate. J Pedriat. 1986;109(1):144-9.
Alagaratnam TT. Idiopathic gynecomastia treated with tamoxifen: a preliminary report. Clin Ther. 1987;9(5):483-7.
McDermott MT, Hofeldt FD, Kidd GS. Tamoxifen therapy for painful idiopathic gynecomastia. South Med J. 1990;83(11):1283-5.
Khan HN, Rampaul R, Blamey RW. Management of physiological gynaecomastia with tamoxifen. Breast. 2004;13(1):61-5.
Ting AC, Chow LW, Leung YF. Comparison of tamoxifen with danazol in the management of idiopathic gynecomastia. Am Surg. 2000;66(1):38-40.
Lawrence SE, Faught KA, Vethamuthu J, Lawson ML. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J Pediatr. 2004;145(1):71-6.
Riepe FG, Baus I, Wiest S, et al. Treatment of pubertal gynecomastia with the specific aromatase inhibitor anastrozole. Horm Res. 2004;62(3):113-8.
Mauras N, Bishop K, Merinbaum D, et al. Phamacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent- onset gynecomastia. J Clin Endocrinol Metab. 2009;94(8):2975-8.
Plourde PV, Reiter EO, Jou HC, et al. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89(9):4428-33.
Petty PM, Solomon M, Buchel EW, Tran NV. Gynecomastia: evolving paradigm of management and comparison of techniques. Plast Reconstr Surg. 2010;125(5):1301-8.
Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol. 2005;23(4):808-15.
Laituri CA, Garey CL, Ostlie DJ, et al. Treatment of adolescent gynecomastia. J Pediatr Surg. 2010;45(3):650-4.
Pitanguy I. Transareolar incision for gynecomastia. Plast Reconstr Surg. 1966;38(5):414-9.
Davidson BA. Concentric circle operation for massive gynecomastia to excise the redundant skin. Plast Reconstr Surg. 1979;63(3):350-4.
Gheita A. Gynecomastia: the horizontal ellipse method for its correction. Aesthetic Plast Surg. 2008;32(5):795-801.
Abramo AC. Axillary approach for gynecomastia liposuction. Aesthetic Plast Surg. 1994;18(3):265-8.
Ohyama T, Takada A, Fujikawa M, Hosokawa K. Endoscope-assisted transaxillary removal of glandular tissue in gynecomastia. Ann Plast Surg. 1998;40(1):62-4.
Chiu DT, Siegel HW. The pinwheel technique: an adjunct to the periareolar approach in gynecomastia resection. Ann Plast Surg. 1999;42(5):465-9.
Pine JL, Smith LJ, Haws MJ, Gingrass MK. Ultrasound-assisted lipoplasty. Plast Surg Nurs. 2003;23(3):101-8; quiz 109.
Maidment SL. Question 2. Which medications effectively reduce pubertal gynaecomastia? Arch Dis Child. 2010;95(3):237-9.
Handschin AE, Bietry D, Hüsler R, Banic A, Constantinescu M. Surgical management of gynecomastia--a 10-year analysis. World J Surg. 2008;32(1):38-44.
LanitisS,StarrenE,ReadJ,etal.SurgicalmanagementofGynaecomastia: outcomes from our experience. Breast. 2008;17(6):596-603.
Gasperoni G, Salgarello M, Gasperoni P. Technical refinements in the surgical treatment of gynecomastia. Ann Plast Surg. 2000;44(4):455-8.
Wiesman IM, Lehman JA Jr, Parker MG, et al. Gynecomastia: an outcome analysis. Ann Plast Surg. 2004;53(2):97-101.
Fruhstorfer BH, Malata CM. A systematic approach to the surgical treatment of gynaecomastia. Br J Plast Surg. 2003;56(3):237-46.
Lejour M. Evaluation of fat in breast tissue removed by vertical mammoplasty. Plast Reconstr Surg. 1997;99(2):386-93.
Goh T, Tan BK, Song C. Use of the microdebrider for treatment of fibrous gynaecomastia. J Plast Reconstr Aesthet Surg. 2010;63(3):506-10.
Hamilton S, Gault D. The tuberous male breast. Br J Plast Surg. 2003;56(3):295-300.
